Palonosetron Hydrochloride Patent Expiration
Palonosetron Hydrochloride is Used for preventing nausea and vomiting caused by chemotherapy and postoperative procedures. It was first introduced by Helsinn Healthcare Sa
Palonosetron Hydrochloride Patents
Given below is the list of patents protecting Palonosetron Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Aloxi | US5202333 | Tricyclic 5-HT3 receptor antagonists |
Apr 13, 2015
(Expired) | Helsinn Hlthcare |
| Aloxi |
US5202333 (Pediatric) | Tricyclic 5-HT3 receptor antagonists |
Oct 13, 2015
(Expired) | Helsinn Hlthcare |
| Aloxi | US7947724 | Liquid pharmaceutical formulations of palonosetron |
Jan 30, 2024
(Expired) | Helsinn Hlthcare |
| Aloxi |
US7947724 (Pediatric) | Liquid pharmaceutical formulations of palonosetron | Jul 30, 2024 | Helsinn Hlthcare |
| Aloxi | US7947725 | Liquid pharmaceutical formulations of palonosetron |
Jan 30, 2024
(Expired) | Helsinn Hlthcare |
| Aloxi |
US7947725 (Pediatric) | Liquid pharmaceutical formulations of palonosetron | Jul 30, 2024 | Helsinn Hlthcare |
| Aloxi | US7960424 | Liquid pharmaceutical formulations of palonosetron |
Jan 30, 2024
(Expired) | Helsinn Hlthcare |
| Aloxi |
US7960424 (Pediatric) | Liquid pharmaceutical formulations of palonosetron | Jul 30, 2024 | Helsinn Hlthcare |
| Aloxi | US8518981 | Liquid pharmaceutical formulations of palonosetron |
Jan 30, 2024
(Expired) | Helsinn Hlthcare |
| Aloxi |
US8518981 (Pediatric) | Liquid pharmaceutical formulations of palonosetron | Jul 30, 2024 | Helsinn Hlthcare |
| Aloxi | US8598218 | Liquid pharmaceutical formulations of palonosetron |
Jan 30, 2024
(Expired) | Helsinn Hlthcare |
| Aloxi |
US8598218 (Pediatric) | Liquid pharmaceutical formulations of palonosetron | Jul 30, 2024 | Helsinn Hlthcare |
| Aloxi | US8598219 | Liquid pharmaceutical formulations of palonosetron |
Jan 30, 2024
(Expired) | Helsinn Hlthcare |
| Aloxi |
US8598219 (Pediatric) | Liquid pharmaceutical formulations of palonosetron | Jul 30, 2024 | Helsinn Hlthcare |
| Aloxi | US8729094 | Liquid pharmaceutical formulations of palonosetron |
Jan 30, 2024
(Expired) | Helsinn Hlthcare |
| Aloxi |
US8729094 (Pediatric) | Liquid pharmaceutical formulations of palonosetron | Jul 30, 2024 | Helsinn Hlthcare |
| Aloxi | US9066980 | Liquid pharmaceutical formulations of palonosetron |
Jan 30, 2024
(Expired) | Helsinn Hlthcare |
| Aloxi |
US9066980 (Pediatric) | Liquid pharmaceutical formulations of palonosetron | Jul 30, 2024 | Helsinn Hlthcare |
| Aloxi | US9125905 | Liquid pharmaceutical formulations of palonosetron |
Jan 30, 2024
(Expired) | Helsinn Hlthcare |
| Aloxi |
US9125905 (Pediatric) | Liquid pharmaceutical formulations of palonosetron | Jul 30, 2024 | Helsinn Hlthcare |
| Aloxi | US9173942 | Liquid pharmaceutical formulations of palonosetron |
Jan 30, 2024
(Expired) | Helsinn Hlthcare |
| Aloxi |
US9173942 (Pediatric) | Liquid pharmaceutical formulations of palonosetron | Jul 30, 2024 | Helsinn Hlthcare |
| Aloxi | US9439854 | Liquid pharmaceutical formulations of palonosetron |
Jan 30, 2024
(Expired) | Helsinn Hlthcare |
| Aloxi |
US9439854 (Pediatric) | Liquid pharmaceutical formulations of palonosetron | Jul 30, 2024 | Helsinn Hlthcare |
| Aloxi | US9457020 | Liquid pharmaceutical formulations of palonosetron |
Jan 30, 2024
(Expired) | Helsinn Hlthcare |
| Aloxi |
US9457020 (Pediatric) | Liquid pharmaceutical formulations of palonosetron | Jul 30, 2024 | Helsinn Hlthcare |
| Aloxi | US9457021 | Liquid pharmaceutical formulations of palonosetron |
Jan 30, 2024
(Expired) | Helsinn Hlthcare |
| Aloxi |
US9457021 (Pediatric) | Liquid pharmaceutical formulations of palonosetron | Jul 30, 2024 | Helsinn Hlthcare |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Palonosetron Hydrochloride Generics
Several generic applications have been filed for Palonosetron Hydrochloride. The first generic version for Palonosetron Hydrochloride was by Sandoz Inc and was approved on Oct 13, 2015. And the latest generic version is by Meitheal Pharmaceuticals Inc and was approved on Aug 14, 2023.
Given below is the list of companies who have filed for Palonosetron Hydrochloride generic.
1. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | injectable | Discontinued | INTRAVENOUS | N/A | Mar 15, 2021 |
2. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 2 different strengths of generic version for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)
(reference standard) | injectable | Prescription | INTRAVENOUS | AP | Apr 21, 2016 |
| EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) | injectable | Discontinued | INTRAVENOUS | N/A | Apr 21, 2016 |
3. TEVA PHARMS USA
Teva Pharmaceuticals Usa has filed for 2 different strengths of generic version for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) | injectable | Discontinued | INTRAVENOUS | N/A | Mar 23, 2018 |
| EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | injectable | Prescription | INTRAVENOUS | AP | Mar 23, 2018 |
4. QILU PHARM HAINAN
Qilu Pharmaceutical Hainan Co Ltd has filed for 2 different strengths of generic version for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Qilu Pharm Hainan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | injectable | Prescription | INTRAVENOUS | AP | Sep 19, 2018 |
| EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) | injectable | Discontinued | INTRAVENOUS | N/A | Sep 19, 2018 |
5. CIPLA
Cipla Ltd has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Cipla.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | injectable | Discontinued | INTRAVENOUS | N/A | Sep 19, 2018 |
6. CHARTWELL RX
Chartwell Rx Sciences Llc has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Chartwell Rx.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | injectable | Prescription | INTRAVENOUS | AP | Sep 19, 2018 |
7. SANDOZ
Sandoz Inc has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | injectable | Prescription | INTRAVENOUS | AP | Oct 13, 2015 |
8. HOSPIRA
Hospira Inc has filed for 2 different strengths of generic version for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Hospira.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | injectable | Prescription | INTRAVENOUS | AP | Sep 19, 2018 |
| EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) | injectable | Discontinued | INTRAVENOUS | N/A | Sep 19, 2018 |
9. MYLAN INSTITUTIONAL
Mylan Institutional Llc has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Mylan Institutional.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | injectable | Prescription | INTRAVENOUS | AP | Sep 19, 2018 |
10. AVET LIFESCIENCES
Avet Lifesciences Ltd has filed for 2 different strengths of generic version for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Avet Lifesciences.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | injectable | Prescription | INTRAVENOUS | AP | Jun 29, 2021 |
| EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)
(reference standard) | injectable | Prescription | INTRAVENOUS | N/A | Jun 29, 2021 |
11. BAXTER HLTHCARE CORP
Baxter Healthcare Corp has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Baxter Hlthcare Corp.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | injectable | Prescription | INTRAVENOUS | AP | Nov 12, 2021 |
12. MEITHEAL
Meitheal Pharmaceuticals Inc has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Meitheal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | injectable | Prescription | INTRAVENOUS | AP | Aug 14, 2023 |
13. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | injectable | Prescription | INTRAVENOUS | AP | Nov 6, 2018 |
14. NOVAST LABS
Novast Laboratories Inc has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Novast Labs.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | injectable | Discontinued | INTRAVENOUS | N/A | May 22, 2020 |
15. FRESENIUS KABI USA
Fresenius Kabi Usa Llc has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Fresenius Kabi Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | injectable | Prescription | INTRAVENOUS | AP | Sep 19, 2018 |
16. SAGENT PHARMS INC
Sagent Pharmaceuticals Inc has filed for 1 generic for Palonosetron Hydrochloride. Given below are the details of the strengths of this generic introduced by Sagent Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | injectable | Prescription | INTRAVENOUS | AP | Sep 19, 2018 |